Beyond COVID-19: Do biothermodynamic properties allow predicting the future evolution of SARS-CoV-2 variants?Research article Published on 2022-12-012022-10-05 Journal: Microbial Risk Analysis [Category] 변종, [키워드] Analysis binding biological property changes in COVID-19 pandemic driving Epidemiological study Evolution Evolution of SARS-CoV-2 Gibbs energy of binding Gibbs energy of growth growth Mechanistic model MERS-CoV Mutation new strain new virus Occurrence pandemic parameter performed predict risk SARS CoV-2 SARS-CoV statistical Strains the SARS-CoV-2 variants of SARS-CoV-2 Virus-host interaction viruses [DOI] 10.1016/j.mran.2022.100232 [Article Type] Research article
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
SARS-CoV-2 cell entry beyond the ACE2 receptorArticle Published on 2022-11-012022-11-16 Journal: Molecular biology reports [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 ACE2 expression ACE2 receptor AGTR2 ASGR1 Asymptomatic auxiliary B.1.1.529 B.1.1.7 B.1.617.1 B.1.617.2 binding carried CD147 CD26 cell entry cell surface receptors CLEC4G Cochrane Library COVID19 Delta Delta+ develop English enzyme erythrocyte Evidence explain facilitate host cell Hypoxemia Infection KREMEN1 LDLRAD3 membrane protein MeSH term neuropilin omicron organs Protein receptor receptors S protein SARS-CoV-2 SARS-CoV-2 cell SARS-CoV-2. SARSCoV-2 selected target therapeutic agent tissue tropism TMEM30A Transmission variants of SARS-CoV-2 viral entry virus entry [DOI] 10.1007/s11033-022-07700-x PMC 바로가기
An outlook on potential protein targets of COVID-19 as a druggable siteArticle Published on 2022-11-012022-11-15 Journal: Molecular biology reports [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] approved cause claimed clinical trial combating contagious COVID-19 COVID-19 disease Cryo-electron microscopy Delta Efficacy feature genomic help host cell host protein infecting inhibit mechanism of action MERS-CoV Mutation non-structural proteins omicron pandemic Protein Protein target proteolytic cleavage raised Repurposed drug required SARS-CoV SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 protein shown similarity spike Spike protein strain suggested the vaccine therapeutic drugs therapeutic interventions Vaccines. variants of SARS-CoV-2 viral infection virus Wuhan X-ray diffraction [DOI] 10.1007/s11033-022-07724-3 PMC 바로가기
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI appear applied approach Blood booster booster vaccination Booster vaccine Cellulose country COVID COVID-19 pandemic decrease evaluate evaluated heterogeneity immune response Immunity immunological protection increase in indicated individual individual level induce median MONITOR NAb Neutralization antibody Neutralizing Neutralizing antibodies neutralizing antibody omicron Omicron variant pandemic POC point of care point-of-care point-of-care test. population level predominant Protective Rapid regimen reported responses against SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants shown stick switching vaccination variant variants of concern variants of SARS-CoV-2 virus neutralization test VoC VOCs waning immunity wild-type [DOI] 10.1128/spectrum.02257-22 PMC 바로가기
Inhibition of the Cell Uptake of Delta and Omicron SARS-CoV-2 Pseudoviruses by N-Acetylcysteine Irrespective of the Oxidoreductive EnvironmentArticle Published on 2022-10-212022-11-16 Journal: Cells [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 ACE2-expressing cell ACE2-expressing cells addition Affect alteration angiotensin-converting enzyme 2 antioxidant approach ascorbic acid binding Cell cell internalization cell receptor Comorbidities COVID-19 Delta dose-dependent Effect Effects Environment evaluated hydrogen peroxide inhibit inhibited inhibition mechanism N-acetyl-L-cysteine N-acetylcysteine NAC omicron Oxidant pharmacological Previous studies produced pseudovirus reactive oxygen species Reactive oxygen species. reactive oxygen specy respiratory viral infection risk ROS SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 spike therapy uptake variant variants variants of SARS-CoV-2 virus uptake [DOI] 10.3390/cells11203313 PMC 바로가기
A comprehensive update on CIDO: the community-based coronavirus infectious disease ontologyArticle Published on 2022-10-212022-11-16 Journal: Journal of Biomedical Semantics [Category] COVID19(2023년), SARS, 변종, 신약개발, [키워드] aligned Amino acid amino acid substitution Analysis applied basic Clinical data clinical trial coronavirus coronavirus coronavirus disease COVID-19 COVID-19 pandemic Delta Diagnosis diagnostic disease domain drug Drug repurposing drug-target effective Epidemiology evaluated example Formal global public health heterogeneous Human Infectious disease initiated knowledge Metadata omicron ontologies Ontology outbreak phenotype PPI protein-protein interaction Safe SARS-CoV-2 SARS-CoV-2 protein Standardization Support supported target protein Treatment Vaccine vaccine. variant variants variants of SARS-CoV-2 virus [DOI] 10.1186/s13326-022-00279-z PMC 바로가기
Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SPArticle Published on 2022-10-132022-11-16 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] “real world” study. Analysis Brazil calculated ChAdOx1 clinical trial comparable Control Coverage COVID-19 COVID-19 disease COVID-19 pandemic death Delta delta variant demographics dose Effectiveness Efficacy eligible first dose Gamma Hospitalization individual initiated Lineage material municipality offered PCR test PCR tests positive raise reduced reported sequenced severe disease severity state Strains Study design symptomatic infection Symptoms unique vaccinated individual vaccinated individuals vaccination Vaccine vaccine dose Vaccines variant variants of concern variants of SARS-CoV-2 [DOI] 10.3389/fpubh.2022.1016402 PMC 바로가기
Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individualsArticle Published on 2022-10-072022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] Affect Alter antibody Antibody Response Antigen antigen exposure antigenic B.1.1.529 boost chronic conditions chronic infection clinical history Cohort COVID-19 COVID-19 pandemic cross-reactive cross-reactive antibody cross-reactivity defined described detectable Diseases epitope glycoprotein healthy high mutation rate highly antigenic immune response immunogenic individual mechanism mutations naïve individual neurological omicron overlapped Pathogens resolved SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 S1 SARS-CoV-2 spike protein serum antibody severe COVID-19 specificity Spike protein Subsequent infection target the antibody response understanding vaccination variants of SARS-CoV-2 Viral antigen virus virus viruses [DOI] 10.1038/s41598-022-20849-6 PMC 바로가기
SARS-CoV-2 Papain-Like Protease: Structure, Function and InhibitionArticle Published on 2022-10-062022-11-15 Journal: Chembiochem [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] antiviral agent antiviral immune response antivirals coronavirus COVID-19 derivatives Epidemic function Host immune response immune immune response in viral inhibition involved ISG15 less MERS-CoV motif other coronaviruses Papain-like protease posttranslational modifications protease protease inhibitors protease inhibitors. Replication SARS-CoV-1 SARS-CoV-2 Structure targets variants of concern variants of SARS-CoV-2 Viral protein [DOI] 10.1002/cbic.202200327 PMC 바로가기